TABLE 2

Clinical characteristics, time to onset and risk factors of immune checkpoint inhibitor-related pneumonitis (ICI-P) in published series

First author [ref.]	Subjects	Type of cancer	ICI-P	Treatment	Patient characteristics	Time to onset	Risk factors for ICI-P
Abdel-Wahab [75]	251 All irAEs	Melanoma 95.6% NSCLC 1.2%	10 (4%)	Ipilimumab 60% Nivolumab 30% Pembrolizumab 10%	Male 63% (total population) Age 60 years (total population) Smokers?	53% during 2nd and 3rd injection (total population)
Naidoo [76]	915	Melanoma 60% NSCLC 20% Other 17%	43 (5%)	aPD-1 93% aPD-L1 7% Combo 44%	Male? Age 67 years Smokers 67%	12 (1.3–82) weeks Mono 19.7 weeks Combo 11.6 weeks	Combo versus mono, 10 versus 3% (p=0.001) aPD-1 versus aPD-L1, 4 versus 1% (p=0.13)
Delaunay [80]	1828	NSCLC 75% Melanoma 20.3% Others 4.7%	64 (3.5%)	Ipilimumab 6.9% aPD-1 79% aPD-L1 14% Trials 9.4%	Male 84.4% Age 59 years Smokers 83%	9.9 (1–117) weeks
Kato [78]	111	NSCLC 100%	8 (7.2%)	Nivolumab 100%	Male 100% Age 65 years Smokers 100%	5.3 (2.3–24) weeks
Suresh [77]	205	NSCLC 100%	39 (19%)	Nivolumab 92% Combo 21%	Male 82% Age 68 years Smokers 95%	2.9 (3–26) weeks	Squamous versus non-squamous RR: 2.29 (1.08 versus 4.83) Female versus male 0.25 versus 0.19 person-year Combo versus mono 0.28 versus 0.18 person-year
Cho [79]	167	NSCLC 100%	22 (13%)	Nivolumab 59% Pembrolizumab 32% Nivolumab–iplimumab 9%	Male 76% Age ≥70 years 30% Smokers 70%	7.7 (2.9–139) weeks	Mono versus combo, 13.6 versus 10% Pembrolizumab versus nivolumab 12.6 versus 16.3% Age ≥70 years, 30.3% versus 54.5%; p=0.025 ILD 18.2% versus 2.8%; p=0.002 Extrathoracic metastasis 31.8% versus 58.6%; p=0.019

Data are presented as n or n (%), unless otherwise stated. irAE: immune-related adverse event; NSCLC: nonsmall cell lung cancer; aPD-1: antibody anti-programmed cell death-1, aPD-L1: antibody anti-programmed cell death ligand-1; combo: combination therapy; mono: monotherapy; ILD: interstitial lung disease.